New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 23.75mg; metoprolol succinate 23.75mg; metoprolol succinate 23.75mg - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; macrogol 400; ethylcellulose; sodium stearylfumarate; macrogol 6000; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; triacetin - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: silicon dioxide; ethylcellulose; hyprolose; microcrystalline cellulose; sodium stearylfumarate; synthetic paraffin; macrogol 6000; hypromellose; titanium dioxide - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; ethylcellulose; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; sodium stearylfumarate; macrogol 6000; povidone; purified talc; croscarmellose sodium; silicon dioxide; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: macrogol 6000; ethylcellulose; sodium stearylfumarate; silicon dioxide; triethyl citrate; microcrystalline cellulose; purified talc; methacrylic acid copolymer; croscarmellose sodium; povidone; silicified microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: triethyl citrate; macrogol 6000; croscarmellose sodium; povidone; sodium stearylfumarate; purified talc; silicon dioxide; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; microcrystalline cellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: purified talc; macrogol 6000; microcrystalline cellulose; povidone; silicon dioxide; triethyl citrate; sodium stearylfumarate; croscarmellose sodium; silicified microcrystalline cellulose; methacrylic acid copolymer; ethylcellulose; titanium dioxide; hypromellose; peg-150 distearate; lauromacrogol 400 - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - pneumococcal purified capsular polysaccharides, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; phenol; sodium chloride - pneumovax 23 is indicated for immunisation of individuals in the following situations: all individuals over the age of 65 years; individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy; immunocompromised patients at increased risk of pneumococcal disease (eg patients with hiv infection before the development of aids, nephrotic syndrome, multiple myeloma, lymphoma, hodgkin's disease and organ transplantation); aboriginal and torres strait islander people over 50 years of age; immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg chronic cardiac, renal or pulmonary disease, diabetes mellitus, alcoholism and cirrhosis); patients with cerebrospinal fluid leaks. in australia, the national health and medical research council (nhmrc) currently recommends the vaccination of tobacco smokers with the 23-valent